NICE rejects Novartis’ Mayzent for secondary progressive MS
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
Read Moreby Selina McKee | Jun 26, 2020 | News | 0
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
Read Moreby Selina McKee | Apr 22, 2020 | News | 0
The data underscore the advantages of early treatment initiation, the firm notes
Read Moreby Selina McKee | Oct 9, 2018 | News | 0
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
Read Moreby Selina McKee | Mar 23, 2018 | News | 0
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.
Read Moreby Selina McKee | Sep 19, 2016 | News | 0
Novartis has unveiled further findings from a late-stage trial of its experimental multiple sclerosis drug BAF312 (siponimod), showing that the drug cut the risk of disability progression in adults with secondary progressive forms of the disease.
Read Moreby Selina McKee | Aug 26, 2016 | News | 0
Novartis’ experimental multiple sclerosis drug siponimod has hit its key target in a late-stage trial, raising hopes for a new treatment option for patients.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
